Previous 10 | Next 10 |
2023-05-23 09:53:00 ET Most biotechs don't have a diversified business model. They typically develop hardware, diagnostic tests, or drugs, as well as some of the associated platform technologies. But a few competitors, like 23andMe (NASDAQ: ME) and Fulgent Genetics (NASDAQ: FL...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development...
2023-05-14 01:47:50 ET Summary We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007, a nano-encapsulated paclitaxel, in treati...
Total Revenue of $66.2 million Record Core Revenue of $62.7 million, growth of 150% year-over-year Raises Full Year 2023 Core Revenue Guidance to $250 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based compa...
2023-05-04 11:16:58 ET Major earning expected before the bell on Friday include: AMC Entertainment Holdings ( AMC ) Dominion Energy ( D ) Enbridge ( ENB ) fuboTV ( FUBO ) Warner Bros. Discovery ( WBD ) For further details see: Notable earn...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results bef...
2023-04-16 14:01:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 mi...
2023-04-11 10:05:56 ET Fulgent Genetics ( NASDAQ: FLGT ) and Mission Bio are collaborating to broaden accessibility of single-cell multi-omics for drug development and clinical research. Fulgent said it is now able to offer single-cell multi-omics on the Tapestri Platform...
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research PR Newswire Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics ...
Fulgent Genetics, Inc. (FLGT) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...